MammaPrint. No Questions, Only Results

As an early-stage breast cancer patients, you want to have confidence in the decisions you make with your physician. You want to know if you are likely to show benefit from chemotherapy for your breast cancer, or not. Receiving an intermediate or ambiguous result, will not provide you with the clarity you need.

Breast Cancer Diagnostic Testing

MammaPrint is a genomic test for women with early-stage breast cancer that helps predict risk of cancer recurrence. A MammaPrint Low Risk result identifies patients who are unlikely to have significant benefit from chemotherapy, sparing them from suffering unnecessary side effects and toxicity. MammaPrint is currently the only U.S. FDA cleared test for risk of recurrence within five years in woman of all ages.

MammaPrint provides “Low Risk” or “High Risk” results. Approximately 75% of the most commonly diagnosed breast cancers are genomically Low Risk with no significant benefit of chemotherapy1, unlike other genomic tests which may give an intermediate result. The Oncotype DX assay, for example, provides intermediate results 39-672,3 percent of the time.

Furthermore, MammaPrint is supported by the highest level of evidence (Level 1A) from the MINDACT study that was recently published in the New England Journal of Medicine.1

MINDACT Publication

1Cardosa F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.

2Carlson JJ, Roth JA. The impact of the Oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Jul; 146(1): 233.

3Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373: 2005-14.